ArticleOncotarget2017
Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinicopathological and prognostic significance of zinc finger antisense 1 overexpression in cancers: A meta-analysis.Medicine · 2018Pooled it
- Long Non-coding RNAs Genes Polymorphisms and Their Expression Levels in Patients With Rheumatoid Arthritis.Frontiers in immunology · 2019Trial
- LncRNA ZFAS1 in hepatocellular carcinoma: A systematic review of molecular mechanisms and clinical translation.Non-coding RNA research · 2026Review
- Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors.Cancer cell international · 2024Review
- BC032913 as a Novel Antisense Non-coding RNA is Downregulated in Gastric Cancer.Journal of gastrointestinal cancer · 2021Article
- Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis.Heliyon · 2021Review
- Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance.International journal of molecular sciences · 2021Review
- LncRNA ZFAS1/miR-1271-5p/HK2 Promotes Glioma Development Through Regulating Proliferation, Migration, Invasion and Apoptosis.Neurochemical research · 2020Article
- Comprehensive analysis of differentially expressed lncRNAs as diagnostic and prognostic markers for colorectal cancer.Experimental and therapeutic medicine · 2019Article
- Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis.Journal of experimental & clinical cancer research : CR · 2019Article
- Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.Cellular and molecular life sciences : CMLS · 2019Review
- Review
- ZFAS1: A novel vital oncogenic lncRNA in multiple human cancers.Cell proliferation · 2019Review
- The Long Non-coding RNA ZFAS1 Sponges miR-193a-3p to Modulate Hepatoblastoma Growth by Targeting RALY via HGF/c-Met Pathway.Frontiers in cell and developmental biology · 2019Article
- ZFAS1 functions as an oncogenic long non-coding RNA in bladder cancer.Bioscience reports · 2018Article
- Review
- The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer.Journal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of long non-coding RNA zinc finger antisense 1 (ZFAS1) has been reported in many types of cancers. We performed a synthetic analysis to clarify its prognostic significance as a cancer molecular-marker. Several databases (including PubMed, Web of Science, Embase together with Wanfang and China National Knowledge Internet database) were retrieved to identify ZFAS1-related articles. A total of eight articles were included in this meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were applied to assess the association between ZFAS1 expression level and overall survival (OS). Odds ratios (OR) were calculated with RevMan 5.3 software to determine the relationship between ZFAS1 expression and clinicopathologic features. The pooled results of the meta-analysis indicated that high ZFAS1 expression level was positively correlated with poor OS (HR = 1.87, 95% CI: 1.38-2.36, p< 0.001) in human solid cancers. The statistical significance was also observed in subgroup analysis stratified by the cancer type, analysis method, sample size and follow-up time. Furthermore, the elevated ZFAS1 expression was significantly related to positive lymph node metastasis (OR = 4.18, 95% CI: 2.70-6.48, p< 0.001). The present results suggest that ZFAS1 might be served as a novel promising biomarker for prognosis in Chinese patients with solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.